Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide

Soft Tissue Sarcoma Clinical Trial

Official title:

A Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide In Patients With Unresectable Or Metastatic Soft Tissue Sarcoma or Malignant Mesothelioma

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT00629343
• Other study ID #: AAAC3255
• Status: Active, not recruiting
• Phase: Phase 1
• First received: February 26, 2008
• Last updated: November 7, 2012
• Start date: October 2007
• Est. completion date: August 2014

Study information

• Verified date: November 2012
• Source: Columbia University
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine safety and toxicity for the combination of Temozolomide and Azacitidine in the treatment of Advanced Soft Tissue Sarcoma or Malignant Mesothelioma. This is a single-center, open-label, single-arm Phase I dose-escalation trial. Patients will be evaluated with complete history and physical as well as laboratory studies (complete blood count, metabolic panel, liver function tests), biopsy, and imaging of all sites of measurable disease. This study will be conducted over the course of 3 years.

Description:

The primary objective of the study is to determine the clinical and laboratory toxicities as well as acceptability/tolerance of this dose schedule of combined drug treatment with temozolomide and azacitidine.

Secondary objectives include determination of biochemical response to azacitidine as defined as change in methylation status. We will specifically be looking at changes in genome wide methylation patterns as determined by two high-throughput platforms:

1. A single nucleotide polymorphism chip-based method (MSNP) for genome wide epigenetic profiling

2. CpG island promoter arrays will be performed to focus on promoter methylation status.

We will also monitor clinical response, time to progression and overall survival.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 28
• Est. completion date: August 2014
• Est. primary completion date: October 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically confirmed soft tissue sarcoma or mesothelioma.

• Ineligible for other high priority national or institutional study.

• Non-pregnant, non-lactating.

• Recurrent or progressive disease defined as an increase in size of any existing tumor mass, or the development of new tumor mass or masses, which is not amenable to definitive surgical therapy.

• Measurable disease defined as lesions that can be measured in at least one dimension by physical examination or by means of medical imaging techniques. Ascites and pleural effusions will not be considered measurable disease.

• Prior chemotherapy is allowed with the exception of prior treatment with Temozolomide or Azacitidine. Patients must have received prior 1st line therapy. There is no upper limit to the number of prior therapies received. Prior treatment with an alkylating agent is acceptable.

• Prior radiation therapy is allowed.

• At least 4 weeks since prior chemotherapy or at least 6 weeks since prior radiation therapy.

• Patients may have had another cancer but there must be convincing clinical evidence that the sarcoma is the disease requiring therapeutic intervention. (i.e. Several sarcoma patients have had had a prior cancer [Hodgkin's disease or breast cancer] treated years previously and then developed a clinically active sarcoma.)

• Clinical parameters: Life expectancy > 3 months, Age > 18 years, Performance Karnofsky performance status of greater than or equal to 60%.

• Required initial laboratory data:

• Absolute neutrophil count > 1,500/mm3

• Hemoglobin > 10.0 g/dl

• Platelet count > 100,000/mm3

• Total Bilirubin < 1.5 times upper limit of normal (ULN) for the laboratory.

• Transaminases: aspartate aminotransferase (AST) or alanine aminotransferase (ALT) levels must be < 2 x ULN. If there is known hepatic metastasis, transaminases may be < 5 times upper limit of normal.

• Serum creatinine levels < 1.5 x ULN.

• Women of child-bearing potential must have a negative serum pregnancy test prior to initiation of treatment.

• Men and women of child-bearing potential must be willing to consent to using effective contraception while on treatment and for a reasonable period thereafter (approximately 3 months).

• Capable of providing written, informed consent. Each patient must be completely aware of the nature of his/her disease process and must willingly give consent after being informed of the procedure to be followed, the experimental nature of the therapy, alternatives, potential benefits, side-effects, risks and discomforts.

• No serious medical or psychiatric illness preventing informed consent or intensive treatment (e.g. serious infection).

• No uncontrolled central nervous system metastases.

Exclusion Criteria:

• Known or suspected hypersensitivity to azacitidine or mannitol

• Pregnant or breast-feeding

• Histology other than soft-tissue sarcoma or mesothelioma

• Active or uncontrolled infection or other serious systemic disease

• Prior treatment with temozolomide or azacitidine

• Pregnant or lactating women

• Uncontrolled central nervous system metastases

• Liver metastases

• Patients will not be excluded if they do not wish to participate in the second biopsy for tissue evaluation

• Subjects who have not had prior chemotherapy.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Mesothelioma
• Sarcoma
• Soft Tissue Sarcoma

Intervention

Drug:
• Azacitidine In Combination With Temozolomide
mg, oral

Locations

Country	Name	City	State
United States	Columbia University Medical Center	New York	New York

Sponsors (3)

Lead Sponsor	Collaborator
Columbia University	Celgene Corporation, Schering-Plough

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The primary endpoint is dose limiting toxicity.		Study Completion	Yes
Secondary	Clinical response, time to progression and overall survival.		Study Completion	Yes